Manulife (Manufacturers Life Insurance)’s Autolus Therapeutics AUTL Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.3K	Sell	25,192 -20,557	-45%	-$32.3K	﹤0.01%	2864
2026 Q1	$63.1K	Sell	45,749 -4,115	-8%	-$6.25K	﹤0.01%	2705
2025 Q4	$99.2K	Buy	49,864 +11,445	+30%	+$17.6K	﹤0.01%	2704
2025 Q3	$62.6K	Hold	38,419	–	–	﹤0.01%	2858
2025 Q2	$87.6K	Buy	38,419 +11,289	+42%	+$18.7K	﹤0.01%	2788
2025 Q1	$42.1K	Sell	27,130 -1,203	-4%	-$2.44K	﹤0.01%	2850
2024 Q4	$66.6K	Sell	28,333 -136,588	-83%	-$462K	﹤0.01%	2894
2024 Q3	$599K	Buy	164,921 +235	+0.1%	+$937	﹤0.01%	2182
2024 Q2	$573K	Sell	164,686 -46,961	-22%	-$203K	﹤0.01%	2155
2024 Q1	$1.35M	Buy	211,647 +146,120	+223%	+$911K	﹤0.01%	1684
2023 Q4	$422K	Buy	+65,527	New	+$250K	﹤0.01%	2249

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s AUTL Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Autolus Therapeutics (AUTL) stake by 45% in Q2 2026, selling an estimated $32.3K and leaving 25,192 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2864.

Manulife (Manufacturers Life Insurance) first reported a position in AUTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.35M in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Manulife (Manufacturers Life Insurance) held 25,192 shares of Autolus Therapeutics worth $40.3K as of Q2 2026.
Manulife (Manufacturers Life Insurance) sold 20,557 Autolus Therapeutics shares in Q2 2026, an estimated $32.3K.
Autolus Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #2864 holding.
Manulife (Manufacturers Life Insurance) first reported a position in Autolus Therapeutics in Q4 2023 and has held it in 11 quarters since.
Manulife (Manufacturers Life Insurance)'s Autolus Therapeutics position peaked at $1.35M in Q1 2024.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.